ER+Ve Breast Cancer by Nita Nair
Session 7 : ER+Ve Breast Cancer
Chairpersons :
Hemant Malhotra, Gurpreet Singh
Speaker :
Nita Nair
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
Author: John F R Robertson
Reference: Lancet. 2017 Dec 17;388(10063):29973005
PrECOG 0102: A randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor (HR)-positive, HER2 negative metastatic breast cancer (MBC) resistant to aromatase inhibitor (AI) therapy
Author: Kornblum N
Conference: 2016 SABCS S1-02
BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2) advanced breast cancer (BC)
Author: M Royce
Conference: 2016 ESMO 2220